Sep. 26 at 5:02 PM
Guardant Health will launch its Shield multi-cancer blood test next month, aiming to detect various cancers early using AI. The company expects the test’s market could expand to
$300 billion by identifying early signals for hundreds of diseases beyond cancer. It also anticipates achieving free-cash-flow positivity by 2028, with annual revenue growing 34% to
$2.2 billion.
Shield, already FDA-approved for early colorectal cancer detection, will allow doctors and patients to receive results for additional cancers starting in October. Pricing is expected to fall below
$1,000, with Medicare reimbursing
$1,500, potentially driving sales above
$500 million by 2028.
Guardant leverages AI and a biobank of over one million cancer cases to expand detection beyond cancer to organs including the brain, heart, lungs, and liver. Analysts see potential annual sales of
$50 billion if cancers are caught early.
$GH $EXAS $GRAL